Perspective Therapeutics (CATX)
Develops image-guided lead-212 cancer therapies with paired lead-203 imaging.
Something off on this page? Send us feedback.
Develops investigational, image-guided radiopharmaceutical therapies for cancers including neuroendocrine tumors, melanoma and solid tumors. Pairs lead-203 imaging with lead-212 treatment candidates and relies on clinical development, isotope supply and time-sensitive regional dose production instead of commercial product sales.
Develops image-guided, peptide-targeted alpha radiopharmaceuticals for cancer. Its theranostic approach uses lead-203 imaging to assess target expression and biodistribution, then pairs the same targeting construct with lead-212 to deliver alpha radiation to cancer cells. Lead programs address SSTR2-positive neuroendocrine tumors, MC1R-positive melanoma and FAP-alpha-positive solid tumors; all remain investigational.
Operates as a clinical-stage developer with grant-funded research and financing or strategic-partner economics rather than product sales. Research and clinical-dose production are centered in Iowa and New Jersey, alongside a planned U.S. manufacturing network. Development depends on patient selection and enrollment, regulatory progress, licensed intellectual property, isotope supply and time-sensitive production and delivery because lead-212 has a 10.6-hour half-life.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 18, 2026 | William Blair | Initiate | Rating: — | |
| Aug 18, 2026 | BMO Capital | Initiate | Rating: —Target: — | Target: $11 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $236.9M · Total debt $4.0M · Total assets $392.0M · Shareholders' equity $323.9M
- Revenue
- $81.0K
- Operating income
- −$29.3M
- Net income
- −$26.8M
No dividends on record.
| Insiders | 6.20% | 7.07M shares | |
|---|---|---|---|
| 1 holder · as of Feb 5, 2026 | |||
| Strategic holders | 27.53% | 31.43M shares | |
| 4 holders · as of Sep 3, 2026 | |||
| Other | 66.27% | 75.65M shares | |
| remainder | |||
114.15M company shares as of Sep 22, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Commodore Capital LPInstitution | 10.46% | 11.94M | filed Feb 9, 2026 |
Lantheus Holdings, Inc.Strategic10 percent owner | 10.13% | 11.56M | filed Sep 3, 2026 |
BlackRock, Inc.Strategic | 6.81% | 7.78M | filed Jul 29, 2026 |
Qatar Investment AuthorityInsider | 6.20% | 7.07M | filed Feb 5, 2026 |
State Street CorporationStrategic | 5.30% | 6.05M | filed Aug 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 4, 2026 | Lantheus Alpha Therapy, LLC | 10 percent owner | −167,149 | $3.15 |
| Sep 3, 2026 | Lantheus Alpha Therapy, LLC | 10 percent owner | −80,783 | $3.11 |
| Sep 2, 2026 | Lantheus Alpha Therapy, LLC | 10 percent owner | −42,129 | $3.11 |
| Sep 1, 2026 | Lantheus Alpha Therapy, LLC | 10 percent owner | −35,769 | $3.12 |
| Aug 31, 2026 | Lantheus Alpha Therapy, LLC | 10 percent owner | −78,145 | $3.14 |
- Novartis (ADR)
Approved SSTR2 NET radioligand therapy and deep platform scale.
- Bristol-Myers Squibb
Phase 3 SSTR2 alpha therapy for GEP-NETs.
- Lantheus
SSTR2 NET therapy and diagnostic pair with commercial rights.
- Telix Pharmaceuticals
FAP theranostics and Pb-212 manufacturing capabilities.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Perspective Therapeutics | $2.96 | +0.15% | $338.7M | — | — | 925.5 | −72.1% |
| Novartis (ADR) | $141.28 | +0.01% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Bristol-Myers Squibb | $62.25 | +0.01% | $127.91B | 13.8 | 9.7 | 2.6 | +5.7% |
| Lantheus | $100.00 | −0.01% | $6.53B | 24.2 | 17.8 | 4.2 | +2.7% |
| Telix Pharmaceuticals | $11.80 | −1.26% | $3.83B | 114.7 | — | 4.1 | +22.2% |
| Median | 22.7 | 15.0 | 4.2 | +4.2% |